International Biotechnology Trust Plc
SRI Style:
Social Style
SDR Labelling:
Unlabelled (No CFD)
Product:
Investment Trust
Fund Region:
USA
Fund Asset Type:
Equity
Launch Date:
06/05/1994
Last Amended:
Dialshifter (
):
Fund/Portfolio Size:
£m
ISIN:
GB0004559349
Sustainable, Responsible
&/or ESG Overview:
Awaiting information from fund manager (as at December 2025)
Primary fund last amended:
Information directly from fund manager.
Sustainable, Responsible &/or ESG Policy:
Investment objective
International Biotechnology Trust plc (the “Company”) has an investment objective to achieve long-term capital growth by investing in biotechnology and other life sciences companies.
Investment policy
The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with suitably experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology. Investments may also be made in related sectors such as medical devices and healthcare services. While the Company’s portfolio is held as one pool of assets, for operational purposes there is a quoted portfolio and an unquoted portfolio. The portfolio is diversified by geography, industry sub-sector and investment size with no single investment in a company normally accounting for more than 15% of the portfolio at the time of investment.
The portfolio is split between large, mid and small-capitalisation companies, primarily quoted on stock exchanges in North America, where the most established and commercial biotechnology and other life sciences companies operating in related sectors are based, though investments may also be made in Europe, Asia and Australia. Investments may also be made into unquoted companies and into funds not quoted on a stock exchange, including venture capital funds. This may include funds managed by the Fund Manager and/or members of its group. The primary purpose of investment in unquoted funds will be to gain exposure to unquoted companies.
The Company may invest through equities, index-linked securities and debt securities, cash deposits, money market instruments and foreign currency exchange transactions. Forward or derivative transactions are not used by the Company.
The Company may borrow from time to time to exploit specific investment opportunities, rather than to apply long-term structural gearing to the Company’s portfolio of investments.
(Source: Annual Report as at December 2025)
SDR Labelling:
Unlabelled (No CFD)
Literature
| Fund Name | SRI Style | SDR Labelling | Product | Region | Asset Type | Launch Date | Last Amended |
|
|---|---|---|---|---|---|---|---|---|
International Biotechnology Trust Plc |
Social Style | Unlabelled (No CFD) | Investment Trust | USA | Equity | 06/05/1994 | ||
|
ISIN: GB0004559349 |
||||||||
Sustainable, Responsible &/or ESG OverviewAwaiting information from fund manager (as at December 2025) |
||||||||
|
Information received directly from Fund Manager |
||||||||
|
Please select what you would like to read:
Sustainable, Responsible &/or ESG Policy:Investment objective International Biotechnology Trust plc (the “Company”) has an investment objective to achieve long-term capital growth by investing in biotechnology and other life sciences companies. Investment policy The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with suitably experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology. Investments may also be made in related sectors such as medical devices and healthcare services. While the Company’s portfolio is held as one pool of assets, for operational purposes there is a quoted portfolio and an unquoted portfolio. The portfolio is diversified by geography, industry sub-sector and investment size with no single investment in a company normally accounting for more than 15% of the portfolio at the time of investment. The portfolio is split between large, mid and small-capitalisation companies, primarily quoted on stock exchanges in North America, where the most established and commercial biotechnology and other life sciences companies operating in related sectors are based, though investments may also be made in Europe, Asia and Australia. Investments may also be made into unquoted companies and into funds not quoted on a stock exchange, including venture capital funds. This may include funds managed by the Fund Manager and/or members of its group. The primary purpose of investment in unquoted funds will be to gain exposure to unquoted companies. The Company may invest through equities, index-linked securities and debt securities, cash deposits, money market instruments and foreign currency exchange transactions. Forward or derivative transactions are not used by the Company. The Company may borrow from time to time to exploit specific investment opportunities, rather than to apply long-term structural gearing to the Company’s portfolio of investments. (Source: Annual Report as at December 2025) SDR Labelling:Unlabelled (No CFD) Literature |
||||||||